Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod

Manoj K Mishra1, Janet Wang, Claudia Silva

  • 1Hotchkiss Brain Institute and the University of Calgary, Calgary, Alberta, Canada.

Insights

Proinflammatory monocytes in the blood are crucial for multiple sclerosis (MS) pathology. The drug laquinimod retains these monocytes in the blood, preventing their entry into the central nervous system (CNS) and reducing disease severity.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Proinflammatory monocytes are implicated in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) pathogenesis.
  • Limited data exists on monocyte blood accumulation, CNS infiltration mechanisms, and medication effects in MS/EAE.

Purpose of the Study:

  • To investigate the dynamics of proinflammatory monocyte accumulation in blood during EAE.
  • To elucidate the mechanisms regulating monocyte CNS infiltration.
  • To determine the impact of laquinimod on monocyte biology and EAE progression.

Main Methods:

  • Monitoring CD11b(+)CCR2(+)Ly6C(high) proinflammatory monocytes in mouse blood and spinal cord during EAE.
  • Correlating monocyte levels with clinical EAE scores.
  • Assessing the effects of laquinimod treatment on monocyte trafficking and CNS markers.

Main Results:

  • EAE induction led to a transient increase in blood proinflammatory monocytes, followed by a decrease at clinical onset.
  • Peak EAE severity correlated inversely with blood monocytes and directly with spinal cord monocytes.
  • Laquinimod treatment prevented EAE, retaining monocytes in blood and reducing their CNS infiltration by downregulating CD62L and matrix metalloproteinase-9.
  • Laquinimod also reduced CNS expression of monocyte chemoattractants CCR2 and CCL2.

Conclusions:

  • Proinflammatory monocyte trafficking into the CNS is critical for MS/EAE disease activity.
  • Laquinimod exerts therapeutic effects by inhibiting monocyte CNS entry.
  • This study reveals a key mechanism of action for laquinimod in MS treatment.

Related Concept Videos